Sandoz Strategy and Business Model

Executive Overview

Sandoz is a pure-play off-patent medicines company focused on generics and biosimilars. Headquartered in Basel, Switzerland, and tracing its origins to 1886, the company became an independent public company in October 2023 after its spin-off from Novartis. Sandoz sells a broad portfolio of small-molecule generics, hospital injectables, anti-infectives, and biosimilars across more than 100 markets. Its commercial footprint is global, with Europe as a core operating base, North America as an important profit pool for biosimilars, and a broad International region spanning emerging and developed markets.

In FY2024, Sandoz reported net sales of approximately USD 10.4 billion. The strategic logic of the business is straightforward but difficult to execute well: use a large, repeat-driven generics base to fund growth in higher-value biosimilars and differentiated off-patent products. That makes Sandoz less dependent on any single blockbuster and more dependent on portfolio breadth, regulatory execution, manufacturing reliability, procurement discipline, and market access. As a newly standalone company, Sandoz is also shaping its own operating model, balance sheet, capital-allocation priorities, and supply chain resilience while trying to strengthen its position as a global leader in affordable medicines after loss of exclusivity.

Sandoz at a Glance

Logo
Common name	Sandoz
Full legal name	Sandoz Group AG
Headquarters	Basel, Switzerland
Ownership	Publicly traded; widely held shareholder base following the 2023 spin-off from Novartis, with no controlling shareholder publicly disclosed as of FY2024
Ticker	SDZ
Exchange	SWX - SIX Swiss Exchange
Market Cap	$38.38B
Revenue (FY2024)	$10.36B
Founding / major historical milestones	Founded in 1886 in Basel; became part of Novartis in 1996; built into a major global generics platform under Novartis; established an early lead in biosimilars; spun off and listed as an independent company in October 2023
Industry or industries	Pharmaceuticals; generics; biosimilars; off-patent medicines
Key products or services	Generic prescription medicines, complex generics, hospital injectables, anti-infectives, and biosimilars across immunology, oncology, ophthalmology, endocrinology, neurology, and supportive care
Geographic footprint	Global, with commercial operations in more than 100 markets and a manufacturing and development footprint centered in Europe with additional presence in North America and Asia
Business segments as officially reported	One global operating segment, with regional disclosure including Europe, North America, and International
Company website	https://www.sandoz.com/

1. What Is the Strategy of Sandoz?

Sandoz describes itself as a leader in off-patent medicines with a purpose centered on expanding access for patients. Using the Playing to Win framework, its strategy can be understood as a deliberate choice to compete at scale in global generics and biosimilars rather than in innovative, patent-protected medicines.

1. 1a. What is the winning aspiration of Sandoz?

   Sandoz’s winning aspiration is to be a leading global off-patent medicines company that improves access to healthcare while generating attractive, durable returns as a standalone business. Public communications since the spin-off have emphasized leadership in generics and biosimilars, dependable supply, and the role of affordable medicines in health-system sustainability. Management has also outlined medium-term ambitions for growth and margin expansion, signaling that “winning” means more than defending market share: it means combining access, scale, profitability, and a stronger biosimilars mix.

2. 1b. Where does Sandoz play?

   Sandoz plays in off-patent medicines globally, with a portfolio spanning small-molecule generics, complex generics, hospital products, and biosimilars. It competes across retail pharmacy, wholesaler, hospital, government tender, and specialty channels. Geographically, it plays broadly, but with particular weight in Europe, North America, and a diverse International region. Therapeutically, it focuses on categories where loss of exclusivity creates scale opportunities and where its development, regulatory, and manufacturing capabilities can be leveraged repeatedly.

3. 1c. How does Sandoz plan to win?

   Sandoz plans to win through a mix of scale, launch execution, supply reliability, portfolio breadth, and disciplined capital allocation. In traditional generics, that means being a dependable low-cost producer with enough manufacturing and regulatory depth to compete in price-sensitive markets without constant disruption. In biosimilars, it means using scientific, regulatory, and commercial capabilities to launch complex products that offer better mix and usually less commoditized economics than plain-vanilla oral generics. An important part of the recipe is also selection: Sandoz does not need to play equally hard in every molecule or every country; it can improve returns by prioritizing products and markets where it has structural advantages.

4. 1d. What capabilities must Sandoz have in place?

   The critical capabilities are regulatory execution, quality systems, global technical operations, Active Pharmaceutical Ingredient (API) and biologics sourcing, biosimilar development, IP and legal management around loss-of-exclusivity launches, commercial contracting, and market access. Sandoz also needs strong portfolio management because its economics depend on thousands of stocking, pricing, and lifecycle decisions rather than on a handful of patented blockbusters. In biosimilars specifically, analytical development, manufacturing process control, device capability, and medical-affairs support are especially important.

5. 1e. What management systems does Sandoz require?

   Sandoz requires rigorous quality and compliance systems, pharmacovigilance, supply-chain planning, product and country profitability management, and capital-allocation discipline. As a standalone company, it also needs governance systems that can replace former Novartis infrastructure while preserving service levels. Performance management has to balance commercial metrics such as launches, tenders, and pricing with operating metrics such as service levels, inventory, inspection readiness, and cash conversion. In a business where one plant issue or one failed launch can move results materially, strong management systems are a strategic necessity rather than a back-office detail.

2. What Are the Current Strategic Initiatives of Sandoz?

Sandoz’s current strategic initiatives reflect both its position as a newly independent company and the economics of the off-patent medicines industry.

Standalone build-out after the Novartis spin-off

Since becoming independent in 2023, Sandoz has been establishing its own corporate systems, governance, capital structure, and operating processes. This is not just an administrative task. For a pharmaceutical manufacturer, stand-alone capability has to extend across quality, procurement, regulatory affairs, finance, information technology, tax, treasury, and supply planning. The goal is to preserve continuity while creating a simpler company focused entirely on off-patent medicines.

Accelerating biosimilars as the main growth engine

Sandoz has been explicit that biosimilars are central to its growth outlook. The company has launched and scaled newer biosimilars in markets such as Europe and the United States, while continuing to advance a broader pipeline. Products such as Tyruko, Pyzchiva, and the U.S. ophthalmology biosimilar CIMERLI illustrate the strategic pattern: select molecules with meaningful clinical relevance and payer savings, launch with strong market-access execution, and use the broader Sandoz commercial platform to scale adoption.

Strengthening the core generics portfolio rather than chasing volume everywhere

Sandoz’s generics base remains the foundation of the company’s revenue and cash generation. The strategic initiative here is not simply to maximize the number of stock-keeping units. It is to optimize the portfolio toward products, dosage forms, and markets where Sandoz has sustainable economics. That can include hospital injectables, anti-infectives, differentiated formulations, and other categories where reliability and technical capability matter more than rock-bottom price alone.

Improving manufacturing resilience and supply reliability

Public commentary from Sandoz consistently emphasizes resilient supply. That makes sense in a sector where shortages can damage both revenue and reputation, and where regulators and governments increasingly care about medicine security. Sandoz has highlighted its manufacturing footprint, especially in Europe, as a strategic advantage. The initiative is to keep service levels high, reduce avoidable disruptions, and support launches with sufficient technical capacity.

Selective business development and capability building

Sandoz appears to view external transactions as a supplement to organic execution, not a substitute for it. The 2024 CIMERLI transaction broadened its U.S. biosimilar presence in ophthalmology. The announced acquisition of Just-Evotec Biologics in 2024 was intended to deepen biologics development and manufacturing capabilities. The pattern suggests a preference for targeted capability and portfolio enhancement rather than large-scale diversification.

Margin expansion through mix, productivity, and simplification

Management has emphasized profitability improvement alongside growth. The most credible levers are better mix from biosimilars and complex products, manufacturing and procurement productivity, SG&A efficiency as a stand-alone company, and tighter portfolio discipline. In other words, Sandoz is not trying to outgrow the economics of the sector with sheer volume; it is trying to improve the quality of that volume.

3. What Is the Business Model of Sandoz?

Sandoz’s business model is the sale of off-patent medicines at scale. That sounds simple, but the economics are shaped by portfolio mix, regulatory timing, manufacturing quality, and channel structure.

• What customers buy: Customers buy prescription medicines that are clinically established but no longer protected by originator exclusivity. In practice, they buy either lower-cost generic versions of small-molecule drugs or biosimilars of complex biologic medicines.
• Recurring versus one-time revenue: Most of Sandoz’s revenue is repeat-driven rather than one-time. Pharmacies, hospitals, and distributors reorder products continuously, especially in chronic-care categories and institutional channels. However, the business also has step-change moments around major product launches, tender awards, patent-loss events, and price resets.
• Revenue model: The model is transactional product sales, not subscription-based. Revenue comes through direct contracts, wholesaler relationships, hospital purchasing, tender systems, and distributor arrangements, depending on market structure.
• Pricing power: Pure pricing power is limited in commodity generics because competition, reimbursement systems, and tenders compress price. Sandoz has relatively more pricing leverage where supply is dependable, competition is thinner, products are technically harder to make, or biosimilars deliver clear but still shared savings versus branded biologics.
• Why business mix matters: Mix is one of the most important economic variables. Biosimilars and complex generics generally offer better strategic value than highly commoditized oral solids. Mature generics provide scale and cash flow; biosimilars provide growth and, in many cases, better margin potential.
• Gross margin drivers: Product mix, API cost, biologics manufacturing efficiency, procurement scale, plant utilization, yield, and customer rebates all matter. Gross margin can be hurt by price erosion, supply disruption, or adverse mix.
• Operating margin drivers: Beyond gross profit, operating margin depends on launch spending, regulatory and quality costs, medical affairs for biosimilars, stand-alone company costs, and the ability to simplify low-return SKUs and markets.
• Cash generation: Cash conversion is driven by EBITDA quality, working-capital discipline, inventory management, capex needs for regulated manufacturing, and the timing of launches and tender wins. In a business like Sandoz’s, cash generation improves when the portfolio is both more differentiated and easier to supply reliably.

4. What Products and/or Services Does Sandoz Sell?

Sandoz mainly sells medicines rather than services. Its portfolio falls into two broad categories: traditional generics and biosimilars.

Generics

This is the larger legacy base of the company and includes a broad range of small-molecule medicines in oral solids, injectables, anti-infectives, and other formulations. These products span primary care and specialty settings and are distributed through retail pharmacy, hospital, and institutional channels. Within generics, the more strategically attractive areas tend to be complex dosage forms, anti-infectives, sterile injectables, and hospital products, where technical know-how and reliable supply can matter more than lowest price alone.

Biosimilars

Biosimilars are the company’s most strategically important growth category. Sandoz has been an early pioneer in this field, with products across supportive care, immunology, endocrinology, oncology, ophthalmology, and neurology. Examples in the portfolio have included brands such as Zarxio, Ziextenzo, Hyrimoz, Erelzi, Omnitrope, Tyruko, Pyzchiva, and CIMERLI. These products generally require more development, regulatory, manufacturing, and commercialization capability than standard generics.

What appears to matter most economically

The mature generics portfolio still appears to provide most of the scale and a large share of current cash generation. Biosimilars, however, are disproportionately important for future growth, mix improvement, and strategic differentiation. That makes Sandoz a hybrid business: part large-scale generics platform, part biosimilar growth company.

5. What Are the Key Competitors or Peers of Sandoz?

Competition is not uniform across Sandoz’s portfolio. Commodity generics can be crowded and price-led, while biosimilars and complex injectables tend to have fewer credible competitors and a greater need for development, medical, and manufacturing sophistication.

6. What Is the Marketing Strategy of Sandoz?

Sandoz’s marketing strategy is far more about access, trust, and account execution than mass consumer promotion. Most of its products are prescription medicines sold through institutional or pharmacy channels, so the commercial task is to secure formulary access, win tenders, support substitution, and convince prescribers, pharmacists, and payers that the company is a reliable supplier.

• Corporate brand as trust signal: The Sandoz name matters, but mainly as shorthand for quality, regulatory credibility, and supply reliability rather than for consumer pull.
• Market-access-led marketing: In many markets, winning depends on reimbursement placement, tender participation, wholesaler support, and contracting with large buyers.
• Scientific and medical engagement for biosimilars: Biosimilars need more education and evidence-based engagement than standard generics, especially with physicians, hospital pharmacists, and payers.
• Trade and channel marketing: Retail and wholesale relationships matter in substitution-driven markets, where shelf availability, purchasing terms, and service levels influence uptake.
• Field execution over brand advertising: Compared with consumer health or patented pharma, Sandoz appears to rely more on account teams, medical affairs, pricing discipline, and channel management than on large promotional campaigns.

In short, marketing is a supporting capability for Sandoz, but a strategically important one. Its role is to convert product availability and cost advantage into realized market share without undermining long-term economics.

7. What Are the Key Customer Segments of Sandoz?

Sandoz serves a diversified set of healthcare customers, though in many markets end demand flows through a relatively concentrated set of intermediaries and institutional buyers.

• Wholesalers and pharmaceutical distributors: These are key customers in many developed markets and strongly influence volume, inventory flow, and pricing realization.
• Retail pharmacies and pharmacy chains: Important for traditional generics, especially where pharmacist substitution is a major source of uptake.
• Hospitals, clinics, and health systems: Critical for injectables, anti-infectives, oncology, ophthalmology, and biosimilars used in institutional settings.
• Government purchasers and tender authorities: In many countries, national or regional tender systems are central to access and volume allocation.
• Group Purchasing Organizations (GPOs) and integrated delivery networks: Especially relevant in the United States for hospital and specialty products.
• Payers and reimbursement authorities: They may not always buy directly, but they strongly shape formulary placement, substitution dynamics, and biosimilar adoption.
• Local distributors in International markets: In certain countries, Sandoz reaches end markets through local distribution partners rather than a fully direct commercial model.

The customer base is diversified by geography and channel, but not completely fragmented. Like many pharmaceutical manufacturers, Sandoz is exposed to concentrated buyers in distribution and institutional procurement.

8. What Is the Sales Model of Sandoz?

Sandoz uses a mixed sales model that combines direct selling to large accounts with wholesaler, distributor, and tender channels. The structure varies by product category and country.

• Retail generics: Typically sold through wholesalers and pharmacy channels, often supported by account management and contract negotiation rather than classic pharmaceutical detailing.
• Hospital and institutional products: Frequently sold through tenders, GPO contracts, or direct institutional relationships.
• Biosimilars: More likely to involve targeted field teams, payer engagement, medical affairs, reimbursement support, and specialty distribution.
• International markets: Often use a mix of local affiliates and third-party distribution partners, depending on scale and regulatory complexity.

This channel structure has real strategic consequences. It can reduce customer intimacy in highly intermediated markets, but it also gives Sandoz efficient reach. It limits pricing freedom in some categories, yet rewards service levels and supply reliability. For consultants, the sales model creates opportunities in key-account design, tender strategy, channel profitability analysis, field-force deployment for biosimilars, and distributor performance management.

9. In What Geographies Does Sandoz Operate?

Sandoz operates globally and reports its business across three broad regions: Europe, North America, and International.

Europe

Europe is both a major commercial region and the center of much of Sandoz’s operational footprint. The company has significant manufacturing, development, and corporate capabilities in European markets, and Europe is especially important for tenders, anti-infectives, hospital products, and biosimilar adoption.

North America

North America, particularly the United States, is strategically important for biosimilars, complex product launches, and profit mix. The market structure is different from Europe: more emphasis on wholesalers, large pharmacy chains, specialty distribution, GPOs, and payer contracting.

International

Sandoz’s International region spans a wide range of markets across Latin America, Asia-Pacific, the Middle East, Africa, and other countries outside Europe and North America. These markets are diverse in regulatory structure, pricing environment, and channel model, which makes portfolio and route-to-market selection important.

Operational footprint

Sandoz’s manufacturing and development footprint is concentrated in regulated pharmaceutical hubs, especially in Europe, with important capabilities in countries such as Austria, Slovenia, Germany, and Spain, alongside commercial organizations in North America and across major international markets. The company is geographically diversified on the revenue side, but its technical operations footprint is more concentrated, which is efficient but also makes operational resilience strategically important.

10. Who Are the Owners of Sandoz?

Sandoz is publicly listed under the ticker SDZ following its October 2023 spin-off from Novartis. As of FY2024, the company had a broadly held shareholder base and no controlling shareholder publicly disclosed. Ownership in practice is institutional and market-based rather than family-controlled, government-controlled, or private-equity-controlled. Because major shareholdings can change over time under Swiss disclosure rules, the most current ownership picture is best obtained from the latest regulatory filings and company disclosures.

11. How Is Sandoz Organized?

At a practical level, Sandoz appears to be organized as a focused global pharmaceutical company around one core business: off-patent medicines.

• External reporting structure: One operating segment, with regional disclosure for Europe, North America, and International.
• Business lens: Internally and strategically, the business is often understood through two portfolio lenses: generics and biosimilars.
• Functional structure: Core global functions include development, technical operations, quality, regulatory affairs, commercial, finance, legal, procurement, and corporate support.
• Regional execution: Commercial execution is adapted by region because pricing systems, substitution rules, and customer channels differ significantly by country.
• Legal structure: Sandoz Group AG sits over a network of operating subsidiaries, manufacturing entities, and local commercial affiliates.

The important point is that Sandoz is not a conglomerate. It is a focused portfolio business whose organizational challenge is balancing global scale and technical consistency with local market access and channel variation.

12. How Does Sandoz Operate?

Sandoz operates by repeatedly executing a pharmaceutical lifecycle that starts after the originator’s exclusivity advantage begins to weaken or expire.

1. Portfolio selection: The company chooses molecules, presentations, and markets where it believes it can achieve acceptable returns.
2. Development: For generics, that can mean formulation work, bioequivalence, and regulatory filing. For biosimilars, it requires more extensive analytical, process-development, clinical, and device-related work.
3. Regulatory approval: Sandoz files with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, while also managing country-specific approvals elsewhere.
4. Manufacturing and sourcing: The company sources APIs and biologic inputs, manufactures dosage forms or biologic product, performs quality release, and manages compliance with Good Manufacturing Practice.
5. Commercial access: Products are launched through wholesalers, pharmacies, hospitals, tenders, GPOs, and distributors, depending on market structure.
6. Lifecycle management: Sandoz manages pricing, packaging, tenders, rebates, contract renewals, and market-share defense as competition evolves.
7. Safety and quality oversight: Pharmacovigilance, inspections, complaint handling, and ongoing quality monitoring are embedded in operations, not separate from them.

The key operational complexity is that Sandoz runs a large portfolio of regulated products with different economics, different market structures, and different manufacturing constraints. Day-to-day success depends on coordination across regulatory, plants, procurement, logistics, finance, and country commercial teams.

13. What Are the Growth Opportunities for Sandoz?

Sandoz’s most plausible growth opportunities are tied to areas where scale, technical capability, and regulatory execution create better economics than commodity generics alone.

• Biosimilar launch wave: This is the clearest growth driver. More biologics are losing exclusivity, and Sandoz has the capability set to participate globally.
• Better mix within generics: Complex generics, injectables, anti-infectives, and other harder-to-make products can support more attractive margins than commoditized oral solids.
• U.S. biosimilar expansion: The United States remains a strategically important opportunity as payer acceptance and formulary adoption continue to improve.
• Portfolio optimization: Exiting low-return SKUs or markets and reallocating resources toward better opportunities can drive profitable growth even without dramatic top-line acceleration.
• Selective M&A and licensing: Bolt-on deals can expand pipeline depth, add commercial presence in specialty areas, or strengthen biologics capabilities.
• Supply reliability as a share-gain lever: In markets prone to shortages or inconsistent service, dependable supply can win share without relying solely on price.
• Emerging markets: Some countries in the International region offer volume growth, though often with more pricing and currency complexity.

The main constraints are also clear: price erosion, concentrated buyers, litigation around launch timing, regulatory inspections, manufacturing disruptions, and the capital intensity of biosimilars. Sandoz has growth options, but most require operational excellence rather than simple market expansion.

14. What Is the History of Sandoz?

• 1886: Sandoz was founded in Basel by Alfred Kern and Edouard Sandoz.
• 20th century: The company developed as a Swiss pharmaceutical and chemicals business and became one of Europe’s important life-sciences groups.
• 1996: Sandoz merged with Ciba-Geigy to form Novartis. The Sandoz name was later used for Novartis’s generics business.
• Early 2000s to mid-2000s: Novartis expanded the Sandoz generics platform through acquisitions including Lek and Hexal/Eon Labs, materially increasing its global scale.
• 2006: Sandoz became an early biosimilars pioneer with one of the first approved biosimilars in Europe.
• 2015: Sandoz launched the first biosimilar approved in the United States, an important milestone for the industry.
• 2023: Novartis completed the spin-off of Sandoz, creating an independent publicly traded off-patent medicines company.
• 2024 and beyond: As a standalone company, Sandoz has focused on strengthening biosimilars, improving mix, and building its own systems, capital structure, and operating discipline.

15. What Are the Key Suppliers to Sandoz?

Suppliers are strategically important to Sandoz because cost, quality, and continuity of supply are central to the economics of generics and biosimilars.

• API suppliers: Providers of Active Pharmaceutical Ingredients are crucial for small-molecule generics. Supply concentration or disruption can directly affect product availability and margin.
• Biologics inputs: Biosimilars require specialized raw materials, cell-culture media, resins, filters, and other biologics manufacturing inputs.
• Excipients and formulation materials: These matter for product performance, manufacturability, and regulatory consistency.
• Primary packaging suppliers: Vials, syringes, stoppers, blister packs, and labels are critical in regulated pharmaceuticals and can become bottlenecks.
• Contract manufacturers and service providers: Some external manufacturing, testing, and development support may be used where it improves flexibility or capability access.
• Logistics and cold-chain partners: Particularly important for biosimilars and temperature-sensitive medicines.

Sandoz’s public disclosures generally emphasize supplier categories and supply risk rather than naming many individual vendors. Strategically, supplier structure matters because single-source exposure, regulatory qualification time, and quality failures can have an outsized effect on launches and service levels.

16. How Does the Supply Chain of Sandoz Function?

Sandoz’s supply chain is a regulated pharmaceutical supply network that has to balance cost, resilience, and compliance.

1. Sourcing: The company procures APIs, biologic inputs, excipients, packaging materials, and equipment from qualified suppliers.
2. Manufacturing: Products are made in a network of internal and, where relevant, external facilities. Manufacturing includes both traditional solid-dose or injectable processes and more complex biologics-related activities.
3. Quality testing and batch release: Finished products go through testing and formal release procedures before shipment, which is essential in pharmaceuticals and can add time and complexity.
4. Inventory and network planning: Sandoz must hold enough inventory to support tenders, institutional demand, and launch ramps without tying up too much working capital.
5. Distribution: Products move through wholesalers, specialty distributors, hospitals, pharmacies, and local channel partners depending on country and product type.
6. Post-market support: The supply chain continues after shipment through complaint handling, recalls if needed, pharmacovigilance coordination, and service-level monitoring.

Supply-chain performance is strategically important for Sandoz because medicine shortages, batch failures, and packaging bottlenecks can quickly erase the advantage of a good portfolio. In biosimilars, the chain is even more demanding because of cold-chain considerations, higher technical complexity, and specialty-channel requirements.

17. What Are the Key Assets of Sandoz?

Sandoz is more asset-intensive than an ordinary branded marketer because regulated manufacturing and product dossiers matter enormously.

• Manufacturing network: Regulated pharmaceutical plants and biologics-related capabilities are among the company’s most important hard assets.
• Regulatory dossiers and market authorizations: Approvals, filings, and product registrations are valuable intangible assets that are difficult and time-consuming to replicate.
• Biosimilar development capabilities: Analytical know-how, process-development expertise, and accumulated regulatory experience are strategic assets even though they are not always fully visible on the balance sheet.
• Portfolio breadth: A large installed product base across countries and channels creates scale advantages in commercial reach and procurement.
• Customer relationships and contracts: Tender positions, wholesaler relationships, institutional access, and payer familiarity matter in repeat-purchase categories.
• Brand trust at the corporate level: The Sandoz name is not the same kind of asset as a consumer mega-brand, but it still has value as a signal of quality and supply reliability.

Asset intensity affects returns in two ways. It creates barriers to entry in biosimilars and harder-to-make generics, but it also raises capital requirements and operating leverage, which means utilization and compliance matter a great deal.

18. What Is the R&D Strategy of Sandoz?

Sandoz’s R&D strategy is focused on off-patent product development rather than discovery of novel medicines. That makes it very different from research-based pharmaceutical companies, but not low-skill or low-value. The company needs sophisticated development capabilities in order to bring complex generics and biosimilars to market reliably and at scale.

• Biosimilars as the priority: Biosimilar development is the most strategically important part of R&D because it can support growth, improve mix, and create barriers to entry.
• Complex generics and formulations: Differentiated dosage forms, sterile products, and technically demanding generics can offer better returns than simple commodities.
• Process and manufacturing science: In off-patent medicines, how a product is made is often as important commercially as the molecule itself.
• Regulatory evidence generation: Development work is tightly linked to bioequivalence, comparability, quality documentation, and approval strategy.
• Partnerships and external capability access: Where useful, Sandoz can supplement internal R&D through licensing, business development, and technical partnerships.

The practical goal of Sandoz R&D is not scientific novelty for its own sake. It is to create a repeatable engine for launching valuable off-patent products on time, with acceptable cost, and with a manufacturable process that can support global supply.

19. What Is the Finance Strategy of Sandoz?

As a newly independent company, Sandoz’s finance strategy is closely tied to credibility as a standalone public business. The main themes are balance-sheet discipline, cash generation, selective reinvestment, and improving profitability through mix and execution.

• Protect financial flexibility: Standalone pharmaceutical manufacturing businesses need liquidity and balance-sheet resilience because quality, supply, or litigation events can be costly.
• Fund organic growth where returns are strongest: Capital is likely to be directed toward biosimilars, technical operations, and product areas where Sandoz has structural advantages.
• Use M&A selectively: Recent activity suggests a preference for targeted capability-building deals rather than large transformational acquisitions.
• Drive margin expansion: Finance strategy supports operational priorities such as procurement savings, SKU simplification, manufacturing productivity, and portfolio pruning.
• Maintain shareholder credibility: As a listed company, Sandoz also has to demonstrate disciplined capital allocation, transparent reporting, and an appropriate balance between reinvestment and shareholder returns.

For Sandoz, finance is not just about leverage. It is about deciding where a dollar of capital earns the best return in a regulated, price-pressured portfolio business.

20. What Major Acquisitions Has Sandoz Made?

Sandoz does not appear to rely on constant large-scale M&A as its main growth engine, but acquisitions have played an important role in building its platform and selectively enhancing capabilities.

• Lek (2002, under Novartis): A formative acquisition that strengthened Central and Eastern European manufacturing and development capabilities.
• Hexal and Eon Labs (2005, under Novartis): Important transactions that materially expanded the scale of the Sandoz generics franchise in Europe and the United States.
• CIMERLI business from Coherus (2024): Added a U.S. ophthalmology biosimilar and broadened Sandoz’s biosimilar commercial footprint in a specialty area.
• Just-Evotec Biologics (announced in 2024): Intended to strengthen biologics development and manufacturing capabilities that support the biosimilars strategy. Because transaction status can change over time, readers should confirm the latest status in current company filings.

The larger pattern is that Sandoz uses M&A selectively: to add scale where it matters, deepen biosimilar capability, or strengthen regional and specialty positions, rather than to become a diversified branded-pharma company.

21. How Companies Like Sandoz Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Sandoz use Umbrex when they want the problem-solving approach and functional depth associated with top-tier consulting, but do not need a full traditional consulting team with all the overhead. For an off-patent medicines company, that can be especially useful in focused, high-value projects tied to strategy, operations, commercial execution, finance, digital, ERP, and AI.

• Biosimilar launch strategy: Build country-by-country launch playbooks for upcoming biosimilars, including market access, pricing, physician adoption, and channel strategy.
• EU tender excellence program: Redesign tender bidding processes, win/loss analytics, and price corridors for hospital and government procurement markets.
• U.S. biosimilar commercial acceleration: Support account segmentation, field-force sizing, payer contracting strategy, and specialty-channel optimization.
• Generics portfolio rationalization: Identify low-return SKUs, overlapping presentations, and unattractive market positions, then create an exit-and-reinvestment roadmap.
• Manufacturing network strategy: Analyze plant footprint, capacity allocation, make-versus-buy decisions, and resilience trade-offs across generics and biosimilars.
• Procurement and supply-risk reduction: Improve API sourcing strategy, supplier dual-sourcing, packaging risk management, and working-capital efficiency.
• Post-spin operating model refinement: Help optimize governance, decision rights, shared services, and performance management as Sandoz matures as a standalone company.
• Bolt-on M&A support: Conduct commercial due diligence, synergy assessment, integration planning, and Day 1 readiness for targeted biosimilar or technical-capability deals.
• Cash and margin improvement: Run focused programs on SG&A productivity, inventory reduction, pricing waterfall analysis, and EBITDA bridge improvement.
• AI and analytics in supply chain and commercial planning: Design pragmatic pilots in demand forecasting, shortage prediction, tender analytics, and sales-force insight generation.